Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Validation of optimized embryo scoring procedures: single-day versus two-day assessment.

Gynecologic and obstetric investigation·2026
Same author

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Cancer research communications·2026
Same author

Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients.

BMJ open·2026
Same author

Urokinase Plasminogen Activator Receptor-Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST).

International journal of cancer·2026
Same author

Clinical Outcome Associated With Beta-Lactam Allergy Labels in Hospitalized Patients in Belgium.

Clinical and translational allergy·2026
Same journal

Integrated multi-omics and single-cell analysis of galectins and immune associations in triple-negative breast cancer.

Translational oncology·2026
Same journal

DAZAP2, regulated by miR-125b, contributes to inflammation-related non-small cell lung cancer progression.

Translational oncology·2026
Same journal

Single-cell and machine learning-based neural regulation signature for prognosis prediction and immunotherapy response in lung adenocarcinoma.

Translational oncology·2026
Same journal

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same journal

Fractionated high-dose vitamin c sustains higher plasma trough concentrations in advanced solid tumors: a phase I clinical study.

Translational oncology·2026
Same journal

Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.

Translational oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2025

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

24.0K

Potentially actionable targets in synovial sarcoma: A tissue microarray study.

Lore De Cock1, Flavia Paternostro2, Ulla Vanleeuw2

  • 1Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

Translational Oncology
|July 19, 2024
PubMed
Summary
This summary is machine-generated.

This study found that key proteins like MAGE-A4, NY-ESO-1, YAP1, TAZ, CXCR4, and BRD9 are expressed in synovial sarcoma (SynSa) tissues. This supports ongoing research into new treatments for this rare cancer.

Keywords:
Actionable targetsImmunohistochemistrySynovial sarcomaTissue microarray

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 20, 2025

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies
09:32

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

24.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pathology

Background:

  • Synovial sarcoma (SynSa) is a common soft tissue sarcoma with limited treatment options for metastatic disease.
  • Novel therapies targeting cancer testis antigens (NY-ESO-1, MAGE-A4), BRD9, YAP1, TAZ, and CXCR4 are under investigation.

Purpose of the Study:

  • To investigate the expression of actionable therapeutic targets in Synovial Sarcoma.
  • To correlate protein expression with clinicopathological data in a large cohort of SynSa samples.

Main Methods:

  • Immunohistochemical analysis of a tissue microarray (TMA) from 91 SynSa samples.
  • Correlation of protein expression (MAGE-A4, NY-ESO-1, YAP1, TAZ, CXCR4, BRD9) with clinicopathological features.

Main Results:

  • High expression rates for MAGE-A4 (69%), NY-ESO-1 (56%), YAP1 (92%), TAZ (51%), CXCR4 (82%), and BRD9 (100%).
  • NY-ESO-1 expression was higher in metastatic lesions compared to primary tumors.
  • No significant prognostic role identified for any of the investigated proteins.

Conclusions:

  • This study provides real-world data on actionable protein expression in SynSa.
  • The widespread expression of these markers supports the clinical relevance of ongoing targeted therapy research for Synovial Sarcoma.